6.1 Acute Coronary Syndromes in ICU Patients

Acute Coronary Syndromes in ICU Patients

Acute Coronary Syndromes (ACS) encompass a spectrum of clinical conditions ranging from unstable angina (UA) to non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). In the critical care environment, diagnosing and managing ACS is uniquely challenging due to atypical presentations, concurrent severe illnesses, and competing risks of thrombosis and hemorrhage.

The Universal Definition of Myocardial Infarction

Understanding the distinction between different types of myocardial infarction is paramount in the ICU. The Fourth Universal Definition of Myocardial Infarction classifies MI into several types, with Type 1 and Type 2 being the most relevant for critical care practitioners.

Type 1 Myocardial Infarction

Type 1 MI is the classic acute coronary event caused by atherothrombotic plaque rupture, ulceration, or erosion resulting in intraluminal thrombus formation in one or more coronary arteries. This leads to decreased myocardial blood flow and ensuing myocyte necrosis. Management is focused on plaque stabilization, restoring coronary blood flow, and preventing further thrombosis.

Type 2 Myocardial Infarction

Type 2 MI is characterized by myocardial necrosis occurring secondary to a condition other than coronary plaque instability that causes a mismatch between myocardial oxygen supply and demand. In the ICU, this is extraordinarily common. Causes include severe hypoxemia, acute anemia, tachyarrhythmias, sustained hypotension, or severe hypertension.

Crucially, treating a Type 2 MI with aggressive antithrombotic therapy (as one would a Type 1 MI) can be harmful, especially if the underlying cause is a gastrointestinal bleed causing anemia and hypotension. The primary treatment for Type 2 MI is always correcting the underlying physiological derangement.

Diagnostic Approach in the Critically Ill

Patients in the ICU are often sedated, intubated, or unable to communicate classic symptoms like substernal chest pain. Therefore, diagnosis frequently relies on a high index of suspicion combined with objective data.

1. Electrocardiography (ECG): A 12-lead ECG should be obtained within 10 minutes of suspected ACS. Dynamic ST-segment changes, new left bundle branch block (LBBB), or new T-wave inversions strongly suggest acute ischemia.
2. Cardiac Biomarkers: High-sensitivity cardiac troponin (hs-cTn) assays are the standard of care. However, troponin elevation in the ICU is multifactorial and can be seen in sepsis, pulmonary embolism, renal failure, and heart failure. A rising or falling pattern of troponin is more indicative of acute injury than a chronically elevated level.
3. Echocardiography: Bedside echocardiography is invaluable for identifying new regional wall motion abnormalities, assessing global ventricular function, and ruling out other causes of shock or chest pain (e.g., aortic dissection, pericardial effusion).

Pharmacological Management of Type 1 ACS

Once a Type 1 ACS is identified, prompt medical therapy is required to halt thrombus propagation.

Antiplatelet Therapy

Dual antiplatelet therapy (DAPT) is the standard of care. This consists of aspirin and a P2Y12 inhibitor.

• Aspirin: A loading dose of 162-325 mg (chewed) followed by 81 mg daily.
• P2Y12 Inhibitors: Options include clopidogrel, ticagrelor, or prasugrel.
  • Ticagrelor is preferred over clopidogrel in ACS due to more rapid and potent platelet inhibition, but causes more dyspnea.
  • Prasugrel is generally reserved for patients undergoing percutaneous coronary intervention (PCI) and is contraindicated in patients with a history of stroke or TIA.

Anticoagulation

Systemic anticoagulation is initiated to prevent further thrombus formation. Options include:

• Unfractionated Heparin (UFH): Preferred in the ICU due to its short half-life and reversibility, especially in hemodynamically unstable patients or those likely to undergo CABG.
• Enoxaparin: A low molecular weight heparin (LMWH). Renally cleared, so dosing must be adjusted or avoided in acute kidney injury.
• Bivalirudin: A direct thrombin inhibitor, often used during PCI, particularly in patients with a history of heparin-induced thrombocytopenia (HIT).

Anti-Ischemic Therapy

• Beta-Blockers: Initiate orally within 24 hours if there are no signs of heart failure, low output state, risk for cardiogenic shock, or other contraindications. They reduce myocardial oxygen demand.
• Nitrates: Sublingual or intravenous nitroglycerin can be used for ongoing ischemic pain, control of hypertension, or management of pulmonary edema. Avoid in right ventricular infarction or recent use of phosphodiesterase inhibitors.
• Statins: High-intensity statin therapy (e.g., atorvastatin 80 mg) should be initiated as early as possible to stabilize plaques.

Interventional Strategies

ST-Segment Elevation MI (STEMI)

The goal in STEMI is immediate reperfusion.

• Primary PCI is the treatment of choice. The goal is a door-to-balloon time of less than 90 minutes (or less than 120 minutes if transferred to a PCI-capable facility).
• Fibrinolysis (e.g., tenecteplase, alteplase) is indicated only if PCI cannot be performed within 120 minutes of first medical contact and there are no contraindications. Fibrinolysis is rarely used in modern urban ICU settings but is critical knowledge for rural or transport medicine.

Non-ST-Segment Elevation ACS (NSTEMI/UA)

The timing of angiography depends on risk stratification.

• Immediate Invasive Strategy (< 2 hours): Indicated for patients with hemodynamic instability, cardiogenic shock, severe left ventricular dysfunction, refractory angina despite medical therapy, or life-threatening arrhythmias (e.g., VT/VF).
• Early Invasive Strategy (< 24 hours): Indicated for patients with elevated troponin, dynamic ST-segment changes, or a high GRACE risk score (>140).

Clinical Scenario

A 68-year-old male is admitted to the ICU with severe community-acquired pneumonia requiring mechanical ventilation. On day 2, his blood pressure drops to 75/40 mmHg, and his heart rate increases to 130 bpm (sinus tachycardia). A routine morning chemistry panel shows a new troponin I elevation to 2.5 ng/mL (normal < 0.04). His hemoglobin has dropped from 11 g/dL to 7 g/dL due to a newly diagnosed large gastric ulcer bleed. An ECG shows sinus tachycardia with non-specific ST-T wave changes.

Management: This patient has a Type 2 myocardial infarction driven by severe oxygen supply-demand mismatch (anemia and hypotension/shock). Administering a heparin drip and dual antiplatelet therapy for this elevated troponin would be catastrophic due to his active GI bleed. The correct management involves aggressive fluid resuscitation, blood transfusion, proton pump inhibitors, and endoscopic evaluation to stop the bleeding, which will correct the ischemia.